TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06152627

Intervention type: BEHAVIORAL
Intervention: Standard of care voice therapy with novice clinician RTSS-Voice documentation
Description: Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.

Intervention type: BEHAVIORAL
Intervention: Standard of care voice therapy with expert clinician RTSS-Voice documentation
Description: Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
Study: NCT04816851

Intervention type: PROCEDURE
Intervention: OZAKI technique
Description: an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
Study: NCT06555588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is based on an integration of Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches for managing symptoms of pain, fatigue, and distress. Participants are trained in behavioral symptom management skills (e.g., activity pacing, mindfulness) with an emphasis on engaging in highly valued activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is designed to provide participants with education, support, and resources for a range of issues relevant to those with advanced cancer (e.g., education on symptoms, body image concerns, and financial concerns).
Study: NCT05850546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: guideline-recommended corticosteroid therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroid
Description: guideline-recommended corticosteroid therapy
Study: NCT05026320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen gel
Description: 10%, bid for 5 days (final application on morning of Day 6)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac gel
Description: 2.32% bid for 5 days (final application on morning of Day 6)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: bid for 5 days (final application on morning of Day 6)
Study: NCT04893278

Intervention type: OTHER
Intervention: Virtual reality
Description: Use of Virtual reality goggles during procedure
Study: NCT04605549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107 2 mg dosing
Description: One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107 4 mg dosing
Description: Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107 8 mg dosing
Description: Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
Study: NCT05626153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine anesthesia care
Description: • Implementing anesthesia management according to current routine practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved anesthesia care
Description: * Encourage regional anesthesia or combined regional-general anesthesia.~* Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~* Encourage extubation in the operating room at the end of surgery.~* Encourage multimodal analgesia after surgery.~* Encourage strict indication for ICU admission after surgery.
Study: NCT06287515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Given by Radiation Therapy
Study: NCT06346691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxofylline
Description: Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaterol
Description: Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
Study: NCT04941573

Intervention type: COMBINATION_PRODUCT
Intervention: Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Description: Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.

Intervention type: COMBINATION_PRODUCT
Intervention: Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Description: Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.

Intervention type: COMBINATION_PRODUCT
Intervention: Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Description: Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.

Intervention type: COMBINATION_PRODUCT
Intervention: Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Description: Hyperpolarized xenon is a contrast imaging agent for lung MR imaging. Inert noble gas xenon is hyperpolarized using Xemed developed technology. The gas is administered to the human subjects as a short seconds-long breath-hold while inside the MRI scanner. Once the gas is inhaled, lung images of HP Xenon distributed within the lung spaces can be acquired. Additionally, xenon follows a similar path to oxygen, dissolving in lung tissue and further in bloodstream.
Study: NCT05889143

Intervention type: DRUG
Intervention: Ezetimibe/Rosuvastatin
Description: Patient treated with Crezet Tablet
Study: NCT05792280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI system
Description: Patients will undergo EUS examination with the assistance of AI system.
Study: NCT06427005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5 mg daily for 14 days followed by a 7-day break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 80-120 mg daily for 14 days, followed by a 7-day break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltitrexed
Description: raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
Study: NCT05857384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL42X
Description: IHL-42X consists of acetazolamide and dronabinol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL42X
Description: IHL-42X consists of acetazolamide and dronabinol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide 250 MG
Description: A solid tablet containing 250 mg acetazolamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol 2.5 MG
Description: A soft gelatin capsules containing 2.5mg dronabinol
Study: NCT06343649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual
Description: Delivery of images to conduct several exercises of Explicit Motor Imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory
Description: Delivery of audio recordings to conduct several exercises of Explicit Motor Imagery
Study: NCT06286397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Clascoterone
Description: Application of 1% clascoterone cream twice daily to affected area for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Application of a vehicle cream to the natal cleft twice daily for 12 weeks
Study: NCT05642208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab step-down
Description: step down dupilumab injections
Study: NCT04593277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Mobile Technology
Description: Use INSPIRE mobile application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Access to a study-specific control website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive telehealth stepped care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive printed SCP materials
Study: NCT05373862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter
Description: Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).
Study: NCT05878860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATSN-201
Description: AAV.SPR-hGRK1-hRS1syn

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATSN-201
Description: AAV.SPR-hGRK1-hRS1syn

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATSN-201
Description: AAV.SPR-hGRK1-hRS1syn

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATSN-201
Description: AAV.SPR-hGRK1-hRS1syn

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATSN-201
Description: AAV.SPR-hGRK1-hRS1syn

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATSN-201
Description: AAV.SPR-hGRK1-hRS1syn
Study: NCT06317636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/kg ketamine infused intravenously over 40 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline infused intravenously over 40 minutes
Study: NCT06475846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5580
Description: HRS5580; low dose
Study: NCT06263283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: session of Kine-Yoga
Description: Daily performance of a Kine-Yoga-PEP intervention supervised by a physiotherapist of the department trained in the Kine-Yoga-PEP intervention at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment
Study: NCT06369831

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-ABSCINT-HER2 PET/CT
Description: 68Ga-ABS011, is a single domain antibody (sdAb) with the capability to bind HER2 tumor antigens very fast, while the unbound fraction is rapidly cleared from the blood. ABS011 is labeled with gallium-68, a short-lived isotope (68Ga, t1/2: 68 min). Combining rapid targeting of HER2, fast clearance and low radiation burden make 68Ga-ABS011 is suited for specific tumor marker whole body PET/CT imaging.
Study: NCT06475846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5580
Description: HRS5580; middle dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5580
Description: HRS5580; middle dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank preparation
Description: blank preparation.
Study: NCT05781087

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography and pressure wire assessment
Description: Non-culprit coronary arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance angiogram
Description: 1.5T
Study: NCT04246528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPIN-SELF Program
Description: The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
Study: NCT05448742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biplanar PSI slope-reducing MOWHTO.
Description: High tibial osteotomy (HTO) is a widely performed procedure in case of varus knee with medial compartment osteoarthritis (OA), with medial-opening wedge version performed more often than lateral-closing wedge one. While in most cases the goal of medial-opening wedge HTO (MOWHTO) is isolated correction of coronal limb alignment, intentional or unintentional increase of posterior tibial slope (PTS) after MOWHTO can occur, however its extent is usually limited and depends on accurate hinge axis placement. One of the ideas developed to improve accuracy of hinge axis placement and accuracy of biplanar correction are Patient-Specific Instruments (PSI). Our intervention is novel, biplanar, medial-opening wedge, posterior tibial slope-reducing high tibial osteotomy aided by PSI, with tibial tuberosity serving as hinge axis.
Study: NCT06467344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACDN-01
Description: ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACDN-01
Description: ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
Study: NCT05230797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc oxide Propolis
Description: antibacterial and anti-inflammatory
Study: NCT06467344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACDN-01
Description: ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.
Study: NCT06334965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous 18F-Choline PET-MRI
Description: before first TARE administration (after work-up procedure) and one month after TARE administration
Study: NCT06451159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 (Biological) - 0.33 ×10^8 cells
Description: KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 (Biological) - 1 ×10^8 cells
Description: KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: cyclophosphamide (CYC)
Description: Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: cyclophosphamide (CYC)
Description: Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: fludarabine (FLU)
Description: Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: fludarabine (FLU)
Description: Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
Study: NCT06631170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.15%
Description: Roflumilast cream 0.15% is applied once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream is applied once daily for 4 weeks
Study: NCT06262932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Assess the effectiveness of repeated bolus dosing strategies of amiodarone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
Study: NCT06086418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % Sodium Chloride
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
Study: NCT04070066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital didactic environment
Description: Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: • Simulated scenario
Description: The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
Study: NCT05376800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828 (Brigimadlin)
Description: BI 907828 (Brigimadlin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828 (Brigimadlin)
Description: BI 907828 (Brigimadlin)
Study: NCT06333652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Intravenous infusion 100 mg/ml
Study: NCT04993677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD40
Description: Given into the vein (IV; intravenously); schedule is cohort-specific

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEA-CD40
Description: Given into the vein (IV; intravenously); schedule is cohort-specific

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Given by IV; schedule is cohort-specific.
Study: NCT05137080

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline
Study: NCT04993677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Given by IV; schedule is cohort-specific.
Study: NCT05889871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard endocrine therapy plus Apatinib
Description: Standard endocrine therapy plus Apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard endocrine therapy plus Apatinib
Description: Standard endocrine therapy plus Apatinib